🇺🇸 SODIUM DIVALPROATE in United States

28 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Creatine Phosphokinase Increased — 3 reports (10.71%)
  2. Blood Pressure Systolic Decreased — 3 reports (10.71%)
  3. Coma — 3 reports (10.71%)
  4. Heart Rate Decreased — 3 reports (10.71%)
  5. Intentional Overdose — 3 reports (10.71%)
  6. Lung Disorder — 3 reports (10.71%)
  7. Sinus Rhythm — 3 reports (10.71%)
  8. Toxicity To Various Agents — 3 reports (10.71%)
  9. Coagulopathy — 2 reports (7.14%)
  10. Drug-Induced Liver Injury — 2 reports (7.14%)

Source database →

Other Neurology approved in United States

Frequently asked questions

Is SODIUM DIVALPROATE approved in United States?

SODIUM DIVALPROATE does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for SODIUM DIVALPROATE in United States?

Sanofi is the originator. The local marketing authorisation holder may differ — check the official source linked above.